222 related articles for article (PubMed ID: 37730108)
1. Disparities in cardio-oncology: Implication of angiogenesis, inflammation, and chemotherapy.
Vera CD; López AR; Ewaneewane AS; Lewis K; Parmisano S; Mondejar-Parreño G; Upadhyaya C; Mullen M
Life Sci; 2023 Nov; 332():122106. PubMed ID: 37730108
[TBL] [Abstract][Full Text] [Related]
2. The Role of Biomarkers in Cardio-Oncology.
Ananthan K; Lyon AR
J Cardiovasc Transl Res; 2020 Jun; 13(3):431-450. PubMed ID: 32642841
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond.
Attanasio U; Di Sarro E; Tricarico L; Di Lisi D; Armentaro G; Miceli S; Fioretti F; Deidda M; Correale M; Novo G; Sciacqua A; Nodari S; Cadeddu C; Tocchetti CG; Palazzuoli A; Mercurio V
Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397436
[TBL] [Abstract][Full Text] [Related]
4. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
[TBL] [Abstract][Full Text] [Related]
5. Role of Cardiac Biomarkers in Monitoring Cardiotoxicity in Chemotherapy Patients.
Battisha A; Sawalha K; Obeidat Y; Patel B
Crit Pathw Cardiol; 2023 Sep; 22(3):83-87. PubMed ID: 37607037
[TBL] [Abstract][Full Text] [Related]
6. Left Ventricular Dysfunction and Chemotherapeutic Agents.
Clasen SC; Wald JW
Curr Cardiol Rep; 2018 Mar; 20(4):20. PubMed ID: 29520629
[TBL] [Abstract][Full Text] [Related]
7. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
[TBL] [Abstract][Full Text] [Related]
8. Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM).
Totzeck M; Aide N; Bauersachs J; Bucerius J; Georgoulias P; Herrmann K; Hyafil F; Kunikowska J; Lubberink M; Nappi C; Rassaf T; Saraste A; Sciagra R; Slart RHJA; Verberne H; Rischpler C
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):792-812. PubMed ID: 36334105
[TBL] [Abstract][Full Text] [Related]
9. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
[TBL] [Abstract][Full Text] [Related]
10. What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?
Andres MS; Pan J; Lyon AR
Clin Oncol (R Coll Radiol); 2021 Aug; 33(8):483-493. PubMed ID: 33832839
[TBL] [Abstract][Full Text] [Related]
11. Identifying cancer patients at risk for cardiotoxicity.
Salvatici M; Sandri MT
Future Oncol; 2015; 11(14):2077-91. PubMed ID: 26198838
[TBL] [Abstract][Full Text] [Related]
12. [Cardiotoxicity of anticancer therapies. Towards the implementation of cardio-oncology units].
Hameau R; Gabrielli L; Garrido M; Guzmán AM; Retamal I; Vacarezza MJ; Greig D; Ocqueteau M; Sánchez C; Pizarro M; Corvalán A; Lavandero S; Castro PF; Martínez G
Rev Med Chil; 2018 Jan; 146(1):68-77. PubMed ID: 29806680
[TBL] [Abstract][Full Text] [Related]
13. Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients.
Ryan TD; Nagarajan R; Godown J
Curr Treat Options Oncol; 2019 May; 20(7):56. PubMed ID: 31129800
[TBL] [Abstract][Full Text] [Related]
14. Organization and implementation of a cardio-oncology program.
Fiuza M; Ribeiro L; Magalhães A; Sousa AR; Nobre Menezes M; Jorge M; Costa L; Pinto FJ
Rev Port Cardiol; 2016 Sep; 35(9):485-94. PubMed ID: 27503589
[TBL] [Abstract][Full Text] [Related]
15. Interactions between cardiology and oncology drugs in precision cardio-oncology.
Kamaraju S; Mohan M; Zaharova S; Wallace B; McGraw J; Lokken J; Tierney J; Weil E; Fatunde O; Brown SA
Clin Sci (Lond); 2021 Jun; 135(11):1333-1351. PubMed ID: 34076246
[TBL] [Abstract][Full Text] [Related]
16. Mathematical modeling of cardio-oncology: Modeling the systemic effects of cancer therapeutics on the cardiovascular system.
Casson CL; John SA; Ferrall-Fairbanks MC
Semin Cancer Biol; 2023 Dec; 97():30-41. PubMed ID: 37979714
[TBL] [Abstract][Full Text] [Related]
17. Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.
O'Hare M; Sharma A; Murphy K; Mookadam F; Lee H
Expert Rev Cardiovasc Ther; 2015 May; 13(5):511-8. PubMed ID: 25843285
[TBL] [Abstract][Full Text] [Related]
18. The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology.
Fatunde OA; Brown SA
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963461
[TBL] [Abstract][Full Text] [Related]
19. Role of cardiovascular magnetic resonance imaging in cardio-oncology.
Saunderson CED; Plein S; Manisty CH
Eur Heart J Cardiovasc Imaging; 2021 Mar; 22(4):383-396. PubMed ID: 33404058
[TBL] [Abstract][Full Text] [Related]
20. Inequity in Cardio-Oncology: Identifying Disparities in Cardiotoxicity and Links to Cardiac and Cancer Outcomes.
Ohman RE; Yang EH; Abel ML
J Am Heart Assoc; 2021 Dec; 10(24):e023852. PubMed ID: 34913366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
